NEWTON,
Mass., June 3, 2024 /PRNewswire/
-- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a
commercial-stage pharmaceutical company pioneering novel cancer
therapies, today announced that the Company granted an aggregate of
9,500 restricted stock units (RSUs) to three newly-hired employees.
These RSU awards were granted as of May 31,
2024 (the "Grant Date") pursuant to the Company's 2022
Inducement Stock Incentive Plan, as amended, as inducements
material to the new employees entering into employment with
Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
In addition, the Company granted an award of 200,000 RSUs to
Michael Method, MD, MPH, MBA, the Company's Senior Vice President,
Clinical Development, with a grant date of May 31, 2024.
Each RSU award will vest over three years, with 33 1/3% of the
shares underlying the RSU award vesting on each of the three
consecutive anniversaries of the Grant Date. The vesting of each
RSU award is subject to the employee's continued service as an
employee of, or other service provider to, Karyopharm through the
applicable vesting dates. In addition, each RSU award will be
immediately exercisable in full if, on or prior to the first
anniversary of the consummation of a "change in control event," the
employee's employment is terminated for "good reason" by the
employee or terminated without "cause" by Karyopharm (as such terms
are defined in the applicable RSU agreement).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies
is fueled by a belief in the extraordinary strength
and courage of patients with cancer. Since its founding,
Karyopharm has been an industry leader in oral compounds
that address nuclear export dysregulation, a fundamental mechanism
of oncogenesis. Karyopharm's lead compound and firstinclass,
oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved
in the U.S. and marketed by the Company in three oncology
indications. It has also received regulatory approvals in various
indications in a growing number of exU.S. territories and
countries, including Europe and
the United Kingdom (as NEXPOVIO®)
and China. Karyopharm has
a focused pipeline targeting indications in multiple high
unmet need cancers, including in multiple myeloma, endometrial
cancer, myelofibrosis, and diffuse large
B-cell lymphoma (DLBCL).
For more information about our people,
science and pipeline, please visit
www.karyopharm.com, and follow us on LinkedIn and on X at
@Karyopharm.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302161223.html
SOURCE Karyopharm Therapeutics Inc.
